专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016108894A1 HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY 审中-公开
标题翻译：人类ALPHA-ENOLASE特异性抗体及其在癌症治疗中的使用方法
公开(公告)号：WO2016108894A1
公开(公告)日：2016-07-07
申请号：PCT/US2014/073013
申请日：2014-12-31
申请人： DEVELPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC , NATIONAL HEALTH RESEARCH INSTITUTES
发明人： TSAI, Shih-Chong , YUAN, Ta-Tung , TSENG, Shih-Chi , LAI, Jiann-Shiun , WU, Chia-Cheng , HUANG, Chao-Yang , TSAI, Ya-Wei , LOK, Ying-Yung , WU, Chung-Hsiun , SHIH, Neng-Yao , LIU, Ko-Jiunn , CHEN, Li-Tzong
IPC分类号： A61K39/00 , C07K16/00
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/28 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENOl (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO:6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO:7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO:3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO:4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.
摘要翻译：人源化抗体或其结合片段，其中所述人源化抗体结合人类ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。

2. 发明公开

EP3240566A1 HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY 有权转让
标题翻译：人源化α-ENO酶特异性抗体及其在癌症治疗中的使用方法
公开(公告)号：EP3240566A1
公开(公告)日：2017-11-08
申请号：EP14909690.1
申请日：2014-12-31
申请人： Development Center for Biotechnology , DCB-USA LLC , National Health Research Institutes
发明人： TSAI, Shih-Chong , YUAN, Ta-Tung , TSENG, Shih-Chi , LAI, Jiann-Shiun , WU, Chia-Cheng , HUANG, Chao-Yang , TSAI, Ya-Wei , LOK, Ying-Yung , WU, Chung-Hsiun , SHIH, Neng-Yao , LIU, Ko-Jiunn , CHEN, Li-Tzong
IPC分类号： A61K39/00 , C07K16/00
摘要： A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENOl (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO:6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO:7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO:3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO:4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

4. 发明申请

WO2018237341A1 A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY 审中-公开
公开(公告)号：WO2018237341A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/039120
申请日：2018-06-22
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , LIN, Tzu-Yin , HUANG, Chao-Yang , CHEN, Yu-Jung , YU, Jei-Hwa , CHIEN, Chen-Li
IPC分类号： A61K39/395 , C07K16/18 , C07K16/00 , C07K16/28 , C07K16/46 , C07K16/30
摘要： An asymmetric heterodimeric antibody includes a knob structure formed in a CH3 domain of a first heavy chain; a hole structure formed in a CH3 domain of a second heavy chain, wherein the hole structure is configured to accommodate the knob structure so that a heterodimeric antibody is formed; and a T-cell targeting domain fused to the CH3 domain of the first heavy chain or the second heavy chain, wherein the T-cell targeting domain binds specifically to an antigen on the T-cell. The T-cell targeting domain is a ScFv or Fab derived from an anti-CD3 antibody. The asymmetric heterodimeric antibody may have L234A and L235A mutations or L235A and G237A such that its effector binding is compromised.

5. 发明申请

WO2014172591A3 HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES 审中-公开
标题翻译：人源化抗IL-20抗体及治疗炎症性疾病
公开(公告)号：WO2014172591A3
公开(公告)日：2014-10-23
申请号：PCT/US2014/034579
申请日：2014-04-18
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , HUANG, Chao-Yang , LIN, Yu-Ying , CHEN, Yu-Jung , LAI, Jiann-Shiun
IPC分类号： C07K16/46
摘要： A humanized antibody, or a scFv, Fab, or F(ab') 2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.
摘要翻译：人源化抗体或其scFv，Fab或F（ab'）2包括：重链可变区或其同源变体，其中所述人源化抗体或其scFv，Fab或F 重链可变区包括：重链框架区，具有SEQ ID NO：19的序列的CDRH1，具有SEQ ID NO：20的序列的CDRH2和具有SEQ ID NO：21的序列的CDRH3，其中所述重链可变区和同源变体在重链框架区中具有至少90％的序列同一性; 和轻链可变区或其同源变体，其包含：轻链构架区，具有SEQ ID NO：22序列的CDRL1，具有SEQ ID NO：23序列的CDRL2和具有SEQ ID NO：23序列的CDRL3 SEQ ID NO：24的序列，其中轻链可变区和同源变体在轻链框架区中具有至少90％的序列同一性。

6. 发明申请

WO2018126232A1 KLK6-MEDIATED CNS-SPECIFIC ANTIBODY PRODRUG ACTIVATION 审中-公开
公开(公告)号：WO2018126232A1
公开(公告)日：2018-07-05
申请号：PCT/US2017/069135
申请日：2017-12-29
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： YU, Jei-Hwa , FONG, Lok-U , HSU, Su-Yi , HU, Chih-Yung , WU, Chia-Cheng
IPC分类号： A61K39/395 , C07K16/00 , C07K16/46 , C07K19/00 , C12N15/09
摘要： An antibody prodrug capable of being selectively activated in a central nervous system (CNS) by protease KLK6 includes an antibody for treating a disease or disorder in the CNS; a KLK6 cleavable peptide fused to an N-terminus of a heavy chain and/or a light chain of the antibody; and a blocker fused to an N-terminus of the KLK6 cleavable peptide. The disease or disorder is a cancer, inflammatory disease, autoimmune disease, infectious disease, or neuron degeneration disease.

7. 发明申请

WO2018017863A1 MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME 审中-公开
标题翻译：修饰的抗结合FAB片段和包含该抗体的抗结合分子
公开(公告)号：WO2018017863A1
公开(公告)日：2018-01-25
申请号：PCT/US2017/043126
申请日：2017-07-20
申请人： DCB-USA LLC , DEVELOPMENT CENTER FOR BIOTECHNOLOGY
发明人： HU, Chih-Yung , HUANG, Chao-Yang , CHEN, Yu-Jung , WU, Chia-Cheng , KUAN, Chien-Tsun , LO, Chia-Hsiang , TSAI, Hsien-Yu
IPC分类号： A61K39/395 , C07K16/46 , C12N15/62 , C12N15/64 , C12N15/66 , C12N15/86
摘要： The present invention provides a modified antigen-binding Fab fragment. An antigen-binding molecule comprising the antigen-binding Fab fragment and a composition comprising the molecule are also provided.
摘要翻译：本发明提供了修饰的抗原结合性Fab片段。还提供了包含抗原结合性Fab片段的抗原结合分子和包含该分子的组合物。

8. 发明申请

WO2018237364A1 ASYMMETRIC HETERODIMERIC FC-SCFV FUSION ANTI-GLOBO H AND ANTI-CD3 BISPECIFC ANTIBODY AND USES THEREOF IN CANER THERAPY 审中-公开
公开(公告)号：WO2018237364A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/039170
申请日：2018-06-22
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , LIN, Tzu-Yin , CHEN, Yu-Jung , HUANG, Chao-Yang
IPC分类号： C07K16/18 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/40
摘要： A bispecific anti-Globo H antibody includes an anti-Globo H antibody that binds specifically to Globo H; and a T-cell targeting domain fused to a CH3 domain of a heavy chain of the anti-Globo H antibody, wherein the T-cell targeting domain binds specifically to an antigen on T-cells; and wherein the anti-Globo H antibody comprises mutations at an effector binding site such that the bispecific anti-Globo H antibody has a diminished effector function. The T-cell targeting domain is a ScFv or Fab from an anti-CD3 antibody.

9. 发明申请

WO2018232349A1 ANTIBODY-DRUG CONJUGATES CONTAINING ANTI-GLOBO H ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2018232349A1
公开(公告)日：2018-12-20
申请号：PCT/US2018/037912
申请日：2018-06-15
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： LEE, Chao-Pin , CGUANG, Shih-Hsien , HSU, Chuan-Lung , CHEN, Yi-Jen , NIEH, Yu-Chin , WEI, Win-Yin , WU, Chia-Cheng
IPC分类号： A61K39/395 , A61K47/64 , A61P35/00 , C07K16/28 , C07K16/30 , G01N33/574
摘要： An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab-(L-D) m , wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

10. 发明申请

WO2018218068A1 HUMANIZED ANTIBODIES AGAINST GLOBO H AND USES THEREOF IN CANCER TREATMENTS 审中-公开
公开(公告)号：WO2018218068A1
公开(公告)日：2018-11-29
申请号：PCT/US2018/034469
申请日：2018-05-24
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , LAI, Szu-Liang , CHEN, Yu-Jung , HU, Chih-Yung , LIN, Tzu-Yin
IPC分类号： A61K39/395 , C07K16/30 , C07K16/44
摘要： A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDRl, HCDR2, and HCDR3 and a light -chain variable domain having three complementary regions consisting of LCDRl, LCDR2, and LCDR3, wherein the sequence of HCDRl is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDRl is KSNQNLLX' SGNRRYZLV (SEQ ID NO: 7, wherein X' is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式